Novartis AG vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Direxion Daily Semiconductor Bear 3X Shares trades at $45.49. The key difference: Novartis AG pays a 3.17% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| NVS | SOXS | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $1.61K |
52-Week Low | $113.50 | $32.50 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $53.99, down 1.64% with a bearish moving average signal but bullish overall technical outlook. The ETF provides 3x leveraged inverse exposure to semiconductors, recently benefiting from sector volatility. A 1:10 stock split is scheduled for July 26, 2026, following a $0.04 dividend payment in June. Recent news highlights SOXS's surge during semiconductor sell-offs, with the ETF gaining attention as a tactical instrument amid AI-driven chip market fluctuations.
SOXS offers leveraged inverse exposure to semiconductor stocks, presenting high-risk, tactical opportunities during sector downturns. The bullish technical signal contrasts with overbought RSI readings, suggesting potential near-term volatility. Key risks include leverage decay, sector reversal momentum, and dependence on semiconductor market weakness. Investors should approach SOXS as a short-term hedging tool rather than a long-term holding due to its inverse structure and high volatility.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →